Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


25.09.2017

1 AJNR Am J Neuroradiol
1 Arch Phys Med Rehabil
1 BMC Neurol
1 J Immunol
1 J Neuroimmunol
4 Lancet Neurol
9 Mult Scler
2 Nat Rev Neurol
3 Neurology
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJNR Am J Neuroradiol

  1. ROGERS DM, Peckham ME, Shah LM, Wiggins RH 3rd, et al
    Association of Developmental Venous Anomalies with Demyelinating Lesions in Patients with Multiple Sclerosis.
    AJNR Am J Neuroradiol. 2017 Sep 14. doi: 10.3174/ajnr.A5374.
    PubMed     Text format     Abstract available


    Arch Phys Med Rehabil

  2. DORSTYN D, Roberts R, Murphy G, Kneebone I, et al
    An online resource to promote vocational interests among job-seekers with multiple sclerosis: a randomized controlled trial in Australia.
    Arch Phys Med Rehabil. 2017 Sep 16. pii: S0003-9993(17)31084.
    PubMed     Text format     Abstract available


    BMC Neurol

  3. HALABCHI F, Alizadeh Z, Sahraian MA, Abolhasani M, et al
    Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations.
    BMC Neurol. 2017;17:185.
    PubMed     Text format     Abstract available


    J Immunol

  4. ROTHE T, Ipseiz N, Faas M, Lang S, et al
    The Nuclear Receptor Nr4a1 Acts as a Microglia Rheostat and Serves as a Therapeutic Target in Autoimmune-Driven Central Nervous System Inflammation.
    J Immunol. 2017 Apr 14. pii: 1600638. doi: 10.4049/jimmunol.1600638.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  5. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Text format     Abstract available


    Lancet Neurol

  6. MOTL RW, Sandroff BM, Kwakkel G, Dalgas U, et al
    Exercise in patients with multiple sclerosis.
    Lancet Neurol. 2017;16:848-856.
    PubMed     Text format     Abstract available

  7. BERMEL RA
    Unravelling neurodegeneration in multiple sclerosis.
    Lancet Neurol. 2017;16:764-766.
    PubMed     Text format    

  8. PLOUGHMAN M
    A new era of multiple sclerosis rehabilitation: lessons from stroke.
    Lancet Neurol. 2017;16:768-769.
    PubMed     Text format    

  9. PETZOLD A, Balcer LJ, Calabresi PA, Costello F, et al
    Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.
    Lancet Neurol. 2017;16:797-812.
    PubMed     Text format     Abstract available


    Mult Scler

  10. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Text format     Abstract available

  11. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Text format     Abstract available

  12. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Text format     Abstract available

  13. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Text format     Abstract available

  14. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Text format     Abstract available

  15. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Text format     Abstract available

  16. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Text format     Abstract available

  17. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Text format     Abstract available

  18. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  19. PATEL M
    Multiple sclerosis: Intrathecal inflammation mediates mood in relapsing-remitting multiple sclerosis.
    Nat Rev Neurol. 2017 Sep 15. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    

  20. SIDAWAY P
    Multiple sclerosis: Concussion during adolescence linked to increased risk of MS.
    Nat Rev Neurol. 2017 Sep 15. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    


    Neurology

  21. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Text format     Abstract available

  22. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Text format     Abstract available

  23. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


    PLoS One

  24. PAUZUOLIS M, Eich T, Burman J
    Quantification of gammadelta T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.
    PLoS One. 2017;12:e0179095.
    PubMed     Text format     Abstract available

  25. CHAMI M, Halmer R, Schnoeder L, Anne Becker K, et al
    Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    PLoS One. 2017;12:e0178622.
    PubMed     Text format     Abstract available

  26. ALSOP J, Medin J, Cornelissen C, Vormfelde SV, et al
    Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
    PLoS One. 2017;12:e0173353.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: